<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968510</url>
  </required_header>
  <id_info>
    <org_study_id>pthswalqol</org_study_id>
    <nct_id>NCT03968510</nct_id>
  </id_info>
  <brief_title>Swalqol in Primary Hyperparathyroidism</brief_title>
  <official_title>The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uşak University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uşak University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Swallow related quality of life before and after parathyroidectomy will be evaluated in
      patients with primary hyperparathyridism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who will undergone parathyroidectomy for primary hyperparathyroidism will be
      included in the study. Swal-Qol and Sf-36 forms will be used for evaluation of quality of
      life before and 1 month after the surgery. The change in the quality of life and swallowing
      related quality of life will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>Quality of life will be evaluated using short form 36</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>parathyroidectomy cases</arm_group_label>
    <description>patients who will be operated for primary hyperparathyroidism</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parathyroidectomy</intervention_name>
    <description>routine parathyroidectomy will be done for the treatment of adenoma</description>
    <arm_group_label>parathyroidectomy cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with primary hyperparathyroidism
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no diagnosis of Alzheimers disease

          -  must be able to swallow tablets Planned operation for primary hyperparathyroidism

        Exclusion Criteria:

          -  secondary or tertiary hyperparathyroidism

          -  insulin dependent diabetes

          -  thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barış Sevinç</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uşak University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barış Sevinç</last_name>
    <phone>+905054880511</phone>
    <email>drbarissevinc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uşak University</name>
      <address>
        <city>Uşak</city>
        <zip>64100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barış Sevinç</last_name>
      <phone>5054880511</phone>
      <email>drbarissevinc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uşak University</investigator_affiliation>
    <investigator_full_name>Barış Sevinç</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

